ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and the Australian Nuclear Science and Technology Organisation (ANSTO), a public research organization and international
Companies will work toward accessing a novel strategy for breaking the tumor microenvironment by combining ITM’s high-quality radioisotopes with Navigo’s precise target-specific affinity ligands against the fibroblast activation protein (FAP)GARCHING/MUNICH, Germany and HALLE/SAALE, Germany, December 02,.
Companies will work toward accessing a novel strategy for breaking the tumor microenvironment by combining ITM's high-quality radioisotopes with Navigo's precise target-specific affinity ligands against
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology's Targeted Radionuclide Therapy candidate FAP-2286 ITM Isotope Technologies